Drug
Ledipasvir clinical trials
Also written GS-5885.
Counted the way a researcher would: Ledipasvir with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2016 (9)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 3 |
| 2013 | 1 |
| 2015 | 6 |
| 2016 | 9 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 20
Gilead Sciences (4) · National Hepatology & Tropical Medicine Research Institute (1) · Tanta University (1) · Fondazione Italiana Linfomi - ETS (1) · Partners in Health (1) · University of Maryland, Baltimore (1) · Assiut University (1) · Almaza Military Fever Hospital (1)
Often tested with
Tested in the same studies.
Sofosbuvir (16) · Ribavirin (7) · Simeprevir (3) · GS-9451 (3) · Daclatasvir (2) · Peginterferon alfa-2a (2) · Salvage Therapy (1) · Velpatasvir (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses ledipasvir is read from its arms, and is right about nine times in ten.
Testing it · 25
- Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCCCompletedPhase 3National Hepatology & Tropical Medicine Research InstituteNCT02771405Written as Ledipasvir
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionCompletedPhase 4Tanta UniversityNCT02992457Written as Sofosbuvir and Ledipasvir
- Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV InfectionCompletedPhase 2Fondazione Italiana Linfomi - ETSNCT02836925Written as Ledipasvir+Sofosbuvir
- PK of SOF/LED in HCV - Infected Adolescents With Haematological DisordersStatus unknownPhase 3Ain Shams UniversityNCT04353986Written as Sofosbuvir and Ledipasvir
- Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing WorldCompletedPhase 4Partners in HealthNCT02964091Written as sofosbuvir/ledipasvir
- Ledipasvir/Sofosbuvir for Hepatitis B Virus InfectionCompletedPhase 2University of Maryland, BaltimoreNCT03312023Written as Ledipasvir 90 MG
- Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19CompletedPhase 4Assiut UniversityNCT04498936Written as Sofosbuvir and Ledipasvir
- Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard TreatmentCompletedPhase 3Almaza Military Fever HospitalNCT04530422Written as Sofosbuvir plus Ledipasvir
- Hepatitis C Virus(HCV) Heart and Lung StudyCompletedPhase 4Duke UniversityNCT02858180Written as Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)
- Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)TerminatedNot applicableMassachusetts General HospitalNCT02503735Written as Sofosbuvir/Ledipasvir FDC
- Extrahepatic Insulin Resistance in Chronic Hepatitis CCompletedNot applicableUniversity Hospital, GenevaNCT02760355Written as Ledipasvir 90 mg/Sofosbuvir 400 mg
- A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 InfectionCompletedPhase 2Janssen Sciences Ireland UCNCT02421211Written as Ledipasvir (LDV)
- Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) StudyTerminatedPhase 4University of Texas Southwestern Medical CenterNCT02717949Written as sofosbuvir/ledipasvir
- Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.WithdrawnPhase 4Kaiser PermanenteNCT03279133Written as Ledipasvir 90mg/Sofosubvir 400mg
- Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1CompletedPhase 3Tehran University of Medical SciencesNCT02705534Written as Ledipasvir
- Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central AfricaCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT02405013Written as Ledipasvir
- DAA in the Risk of Recurrence After Curative Treatment of HCCWithdrawnPhase 4Taipei Veterans General Hospital, TaiwanNCT02959359Written as Ledipasvir 90mg/Sofosbuvir 400 mg
- Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)CompletedPhase 4Instituto de Investigación Marqués de ValdecillaNCT02768961Written as ledipasvir
- Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIVCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01878799Written as GS-7977/GS- 5885 FDC
- Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)TerminatedPhase 3University Health Network, TorontoNCT02478229Written as Sofosbuvir (SOF) and Ledipasvir (LDV)
See all 25 studies that test ledipasvir →
Given in every arm · 5 — ledipasvir is usual care beside what is tested
- Combination Therapy for Chronic Hepatitis C InfectionCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01805882Written as Ledipasvir
- Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3CompletedPhase 2Gilead SciencesNCT01260350Written as LDV
- GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C VirusCompletedPhase 2Gilead SciencesNCT01356160Written as GS-5885
- GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) InfectionCompletedPhase 2Gilead SciencesNCT01434498Written as GS-5885 tablet
- GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) InfectionCompletedPhase 2Gilead SciencesNCT01435226Written as GS-5885
As the comparator · 1 — what is tested is compared with ledipasvir
Codes
What other systems call ledipasvir · ClinicalTrials.gg INT006436
- MeSH (NLM) C586541ledipasvirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 013TE6E4WVLEDIPASVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1591922Confirmed FDA, Wikidata
- Wikidata Q15409409ledipasvirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C129019LedipasvirOne source FDA
- DrugBank DB09027One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C586541 | ledipasvir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 013TE6E4WV | LEDIPASVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1591922 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15409409 | ledipasvir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C129019 | Ledipasvir | One source FDA |
| DrugBank | DB09027 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.